A drug developed based on induced pluripotent stem cells (iPS cells) for the treatment of Parkinson's disease has been partially approved in Japan.
AzEdu.az reports that this information was provided by the Center for iPS Cell Research and Application (CiRA) at Kyoto University.
"This is a big step forward. We will do our best to ensure that this treatment method becomes a reliable standard option as soon as possible," said Jun Takahashi, the institute's director.
The developed preparation contains nerve cells grown from iPS cells. These cells are intended for transplantation into patients suffering from Parkinson's disease.
In April last year, Kyoto University presented clinical trial results showing positive changes observed in some patients after the transplantation of these cells. In August, "Sumitomo Pharma" applied for approval of the product under the trade name "Amshepuri", and the document was reviewed under an accelerated procedure.
Additionally, another drug based on iPS cells, intended for the treatment of ischemic cardiomyopathy, has also received partial approval. It is noted that both preparations are unique in their kind and currently have no analogues in the world.
